Our mission is to reduce bias and ensure rigorous, consistent, and high-quality results in the field of clinical research. With our central rating service, we offer a comprehensive solution that delivers on these objectives.
Our team of research clinicians, led by Professor Dr Cameron Lacey, brings a wealth of experience to the table. As primary investigators in numerous trials, they have worked closely with contract research organisations (CROs), pharmaceutical companies, and various clinical trial sites. This experience gives them a deep understanding of the unique challenges and considerations involved in conducting successful clinical trials.
For Sponsors and CROs
By leveraging our central rating service and mental health expertise, contract research organizations and pharmaceutical companies can benefit from unbiased, rigorous, and expert evaluations that meet the highest standards of quality. Our experience with phase 1-3 psychedelic trials provides unique expertise to support this rapidly expanding area.
For Trial Sites
By collaborating with our team, clinical trial sites can expand their range of research and gain immediate access to our clinicians' expertise in areas where they may not have been actively involved before. This partnership empowers sites to broaden their research scope and explore new avenues of clinical research.
ee-lim-bi-as
Elimbias (meaning eliminate the bias) has a strong focus on innovative mental health research - particularly psychedelics. With the estimated $2 billion investment in this sector, we are well placed to handle the nuances and needs of this emerging sector.
